Benefit-Risk Assessment Flashcards
7 cards from real PVC practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Benefit-Risk Assessment flashcards as text
Which patient population factor most commonly shifts a benefit-risk balance from unfavorable to favorable for a high-risk drug?
Answer: Patients with severe, life-threatening disease with no adequate alternative therapy
For patients with serious conditions lacking alternatives, even substantial risks may be outweighed by significant clinical benefits, shifting the balance favorably.
The EMA's Benefit-Risk Methodology Project recommended which structured framework as most suitable for regulatory benefit-risk assessment?
Answer: PrOACT-URL
The EMA Benefit-Risk Methodology Project concluded that PrOACT-URL (Problem, Objectives, Alternatives, Consequences, Trade-offs, Uncertainty, Risk tolerance, Linked decisions) is well-suited for regulatory use.
When assessing benefit-risk for a biosimilar, which unique consideration differs from assessment of a novel drug?
Answer: Benefit-risk relies heavily on extrapolation from the reference product's established profile
Biosimilar benefit-risk assessment uses the reference product's established profile as the foundation, with extrapolation to indications based on demonstrated similarity.
A company conducts a Periodic Benefit-Risk Evaluation Report (PBRER). The primary regulatory purpose of this document is to:
Answer: Present a cumulative reassessment of the product's benefit-risk balance at defined intervals
The PBRER provides a cumulative, interval-based benefit-risk reassessment integrating all new data to determine whether the profile remains favorable.
Which type of risk minimization measure goes beyond the standard product label to actively restrict prescribing or dispensing?
Answer: Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU)
REMS with ETASU impose specific conditions such as certified prescribers, pharmacies, or patient enrollment to ensure safe use beyond standard labeling.
In benefit-risk terminology, 'risk tolerance' refers to:
Answer: The level of risk decision-makers and patients are willing to accept given the expected benefits
Risk tolerance reflects the willingness of stakeholders—regulators, patients, and clinicians—to accept a given level of risk in exchange for the anticipated benefits.
A product's benefit-risk profile is re-evaluated after a new safety signal emerges post-approval. This reassessment should include:
Answer: Updated benefit data, the new risk data, and any changes in the therapeutic context
A comprehensive reassessment integrates updated benefit evidence, the new risk information, and changes in treatment alternatives or disease context.